GeneDx Corp.
Rating
Updated: Aug 21, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as ...
Latest News
2 days ago · defenseworld.net
Kevin Feeley Sells 3,728 Shares of GeneDx (NASDAQ:WGS) StockGeneDx Holdings Corp. (NASDAQ: WGS - Get Free Report) CFO Kevin Feeley sold 3,728 shares of GeneDx stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total value of $363,890.08. Following the sale, the chief financial officer directly owned 44,945 shares in the
27 days ago · gurufocus.com
GeneDx Holdings Corp (WGS) Shares Surge 3.3% -- What GF Score of 65 Tells InvestorsOn August 26, 2026, GeneDx Holdings Corp (WGS) shares rose 3.3%, bringing the current price to $90.28. The stock is trading within a 52-week range of $32.21 to
29 days ago · businesswire.com
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children'sGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Seattle Children's show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.
1 month ago · zacks.com
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
1 month ago · seekingalpha.com
GeneDx: Why I Think The Worst Is Behind The BusinessGeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations and testing volumes up 32%. Reimbursement rates have stabilized, and management expects meaningful improvements in Q4 and a stronger recovery in 2027. Valuation remains attractive, with a Buy rating maintained. Upside potential exists if reimbursement and growth targets are met.
1 month ago · gurufocus.com
Is GeneDx Holdings Corp (WGS) Overvalued After 5.1% Rally? GF Value Says OvervaluedOn August 11, 2026, GeneDx Holdings Corp (WGS) shares rose 5.1% to $81.83, bouncing back in a volatile market. Over the past 52 weeks, the stock has traded betw
1 month ago · businesswire.com
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and EpilepsyGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx launches a new online offering to expand access to exome testing and help more children and families get answers sooner.
2 months ago · businesswire.com
GeneDx to Participate in Upcoming Investor ConferencesGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the Canaccord Genuity and Wells Fargo investor conferences.
2 months ago · seekingalpha.com
GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call TranscriptGeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript
2 months ago · marketbeat.com
GeneDx Q2 Earnings Call HighlightsGeneDx NASDAQ: WGS reported second-quarter revenue of $114.4 million, above its prior guidance, as exome and genome testing volume reached a quarterly record of more than 30,000 tests. The company also returned to adjusted profitability one quarter earlier than previously expected, while maintaining its full-year 2026 outlook.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove WGS